Clinical Trials
44 trialsAdding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
SWOG Cancer Research Network
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)
National University Hospital, Singapore
CARABELA
Spanish Breast Cancer Research Group
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
ORIENTA
Guangdong Provincial People's Hospital
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
Yonsei University
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Green3Bio, Inc.
PORTRAIT
Vall d'Hebron Institute of Oncology
NeoSTEP
Shanghai Jiao Tong University School of Medicine
CAT
The Methodist Hospital Research Institute
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Morphotek
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
Calithera Biosciences, Inc
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Shanghai Gynecologic Oncology Group
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
TandHER
Centre Hospitalier Universitaire de Besancon
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Hallym University Medical Center
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
SYSUGO-005
Sun Yat-sen University
xenoZ
University of Pisa
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Masonic Cancer Center, University of Minnesota
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
Hoffmann-La Roche
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
AICE
Shanghai Gynecologic Oncology Group
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Hoffmann-La Roche
Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
Bayer
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Biogen
TABEA
GBG Forschungs GmbH
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
Bristol-Myers Squibb
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer
Bristol-Myers Squibb
A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer
Bristol-Myers Squibb
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
Bristol-Myers Squibb